Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi's tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

The Company announced the record date to be on Jan. 7, 2026, and the related distribution date for the dividend has not been determined by the board of directors of Datavault AI (the “Datavault Board” ...